Cartalax

FDA APPROVAL PENDING

Preclinical

Healing

Longevity

Cartalax

Cartilage Bioregulator | Joint Health & Longevity

Learn more

Healing

Cartalax

Longevity

Amino acid sequence

3

Amino acids

333.29da

Molecular weight

Peptide

Type

Cartalax is a synthetic tripeptide (Ala-Glu-Asp) developed at the St. Petersburg Institute of Bioregulation and Gerontology as a cartilage-specific peptide bioregulator. It modulates gene expression in chondrocytes and fibroblasts, promoting extracellular matrix synthesis and suppressing degenerative signaling pathways. Used in longevity and joint health research, it is primarily studied in Russian preclinical models with no registered Western clinical trials.

Top researched benefits

Overview of Cartalax

Cartalax operates through epigenetic bioregulation in chondrocytes, upregulating synthesis of Type II collagen and aggrecan while downregulating matrix metalloproteinases (MMPs) responsible for cartilage degradation. It also reduces caspase-3 expression in chondrocyte cell lines and has been linked to increased SIRT6 activity, suppressing aging-associated markers p16, p21, and p53.

joint health

  • Clinical efficacy shown in osteochondrosis, osteoarthritis, and osteoporosis treatment.
  • Supports cartilage maintenance and joint function.
  • Supports bone and connective tissue healing.

skin health

  • Increased Ki-67 expression with suppressed apoptosis in young and aged cells.
  • Enhances collagen synthesis in connective tissue.
  • Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.

Typical Dose

10mg per injection

Frequency

once daily

Cycle Duration

10 consecutive days, repeated every 3–6 months

Storage

Lyophilized: -20°C for long-term stability, protected from light and moisture. Reconstituted: 2–8°C for up to 28–30 days, avoid freeze-thaw cycles.

Chemical Makeup

Key benefits

Upregulates Type II collagen and aggrecan synthesis in chondrocytes, supporting cartilage matrix integrity and thickness

Downregulates matrix metalloproteinases (MMPs), slowing enzymatic degradation of articular cartilage

Reduces caspase-3 expression in chondrocyte cell lines, decreasing apoptosis in joint tissue

Increases SIRT6 activity and suppresses p16, p21, and p53 markers, decelerating cellular aging in cartilage

Community interest

This peptide is still gaining traction in the community.

Cartilage Bioregulator | Joint Health & Longevity

This overview is informational and based on aggregated descriptions from studies and user reports.

Was it helpful?Yes
No

Cartalax Molecular Information

View the scientifc details of Cartalax.

3

Amino Acids

Cartalax

Ala

Ala

Position 1

Glu

Glu

Position 2

Asp

Asp

Position 3

Amino acid sequence
AlaninePosition 1
Glutamic acidPosition 2
Aspartic acidPosition 3

Molecular Weight

333.29Da

Chain Length

3Amino Acids

Type

Peptide

Cartalax Protocols

Subcutaneous injection is the exclusively documented delivery route for Cartalax, a tripeptide bioregulator (Ala-Glu-Asp) targeting cartilage and connective tissue regeneration. Injections are administered once daily for 10–20 consecutive day courses, 2–3 times per year, with the preferred site being the abdomen or near the affected joint.

GoalDosageFrequencyRoute
Cartilage repair and early osteoarthritis2001 day rangeSubQ near affected joint
Cellular senescence and gene expression modulation501 day rangeSubQ
Systemic anti-aging and gerontology1001 day rangeSubQ
Tissue-specific protein synthesis support1001 day rangeSubQ near target tissue
Chronic joint health maintenance (between intensive courses)2003 week rangeSubQ
Connective tissue and extracellular matrix homeostasis201 day rangeSubQ

Reconstitution Instructions

Materials needed:

Cartalax lyophilized powder vial (5 mg or 20 mg)Bacteriostatic water (2.0 mL per 5 mg vial or 3.0 mL per 20 mg vial)Insulin syringes (0.5–1 mL, 29–31 gauge, 0.5-inch needle)Alcohol prep padsSharps disposal container

Steps to reconstitute

  1. Allow the Cartalax lyophilized vial to reach room temperature for 10–15 minutes before reconstitution.
  2. Wipe the vial stopper with an alcohol prep pad and allow it to air-dry for 30 seconds.
  3. Draw 2.0 mL of bacteriostatic water into a syringe for a 5 mg vial, yielding a 2.5 mg/mL (2,500 mcg/mL) concentration. For a 20 mg vial, draw 3.0 mL to yield approximately 6,670 mcg/mL.
  4. Insert the needle through the vial stopper and inject the bacteriostatic water slowly down the inside wall of the vial — never directly onto the powder.
  5. Gently swirl or roll the vial between your palms until the powder is fully dissolved. Do not shake the vial.
  6. Store the reconstituted vial in the refrigerator at 2–8°C and use within 28 days.
  7. For each injection, wipe the vial stopper with a fresh alcohol prep pad, then draw the desired dose into an insulin syringe. For a 50 mcg dose from a 2.5 mg/mL solution, draw 0.02 mL (2 units on a U-100 syringe); for a 200 mcg dose, draw 0.08 mL (8 units).
  8. Pinch a fold of skin at the injection site (abdomen, thigh, or near the affected joint), insert the needle at a 45–90 degree angle, and inject slowly and steadily without aspirating.
  9. Rotate injection sites with each dose to avoid localized tissue irritation or lipohypertrophy.

Cartalax Cycle

The Cartalax Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.

Taking breaks between cycles may help maintain effectiveness and support better overall results.

Week 1-2
Establishing baseline; minimal noticeable changes
Week 3-4
Gradual improvement in joint comfort
Week 0-0
Noticeable mobility improvements
Week 0-0
Maximum therapeutic effect achieved

Dosing tools

Cartalax Peptide Dosage Calculator

Calculate peptide doses with our visual syringe guide.

mg

Enter the total amount of peptide in the vial in milligrams (as stated on the label).

The dose you want to inject per administration, in mcg or mg.

1,000 mcg = 1 mg

1 mL

2 mL

3 mL

5 mL

Custom

Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.

Injection Results

Based on your vial and dilution inputs.

Cartalax

SINGLE COMPOUND

Volume per injection

0.05

mL

Concentration

10.00

mg/mL

Doses per vial

20

doses

Total injections per vial

20 injections

How it works

Based on a 10 mg Cartalax vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.

1mL / 100 units

5 units

0.050 mL

Reference Guide

Dosing Cycle

Peptide
Cartalax
Dosing
10mg per injection
Dosing Frequency
once daily
Cycle Duration
10 consecutive days, repeated every 3–6 months
Storage
Lyophilized: -20°C for long-term stability, protected from light and moisture. Reconstituted: 2–8°C for up to 28–30 days, avoid freeze-thaw cycles.

Note: Triple agonist; microdose for fewer side effects

Reconstitution Tips

  • Use bacteriostatic water (BAC)contains 0.9% benzyl alcohol for preservation
  • Inject water slowlyaim down the vial wall, not directly onto powder
  • Never shakegently swirl or roll the vial until dissolved
  • Store properlyrefrigerate at 2-8°C after reconstitution
  • Use within 28 daysmost reconstituted peptides remain stable for about 4 weeks
  • Keep sterilealways clean vial tops with alcohol before drawing

Peptide Interactions

Research suggestions of Cartalax interactions with other common peptides and substances.

Healing

bpc

Longevity

BPC-157

COMPATIBLE

Different mechanisms; no direct interaction.

COMPATIBLE

Healing

tb5

Longevity

TB-500

COMPATIBLE

Distinct action pathways; may complement effects.

COMPATIBLE

Side effects

Contraindications

Pregnancy and breastfeeding

Active cancer (theoretical proliferation risk)

Stop signs

Allergic reactions

Digestive upset (rare with proper administration)

No improvement after 3 months

Unexpected symptoms

Bad signs

Missing holographic seals or professional packagingUnclear dosing instructions
Was it helpful?Yes
No

Comments

0.0

0 reviews

5

4

3

2

1

No comments yet

Be the first to share your experience. Your review helps others make more informed decisions.

Frequently asked questions

What is a peptide dosage calculator?

A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.

How do I calculate peptide dosage from a vial?

To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.

How much Bacteriostatic water should I add to a peptide vial?

Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.

How are peptides different from proteins?

Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.​

CartalaxResearch References

Cartalax is a preclinical compound

4Research references

Cartalax

Cartalax is a preclinical compound

Fibroblast Proliferation Study

Human skin fibroblasts; 72 hours at 20 nM. Increased Ki-67 expression with suppressed apoptosis in young and aged cells.

2019

Kidney Cell Culture Research

Renal epithelial cells; 7 days. Reduced pro-apoptotic p53 expression in aging kidney cells.

2020

Clinical Spine & Joint Study (Russia)

Human subjects; 1-3 months with 0.1mg capsules daily. Efficacy in osteochondrosis, osteoarthritis, and osteoporosis treatment.

n.d.

Matrix Metalloproteinase Research

Fibroblast cultures; 5 days at 20 nM. Inhibited MMP-9 synthesis; maintained extracellular matrix integrity.

2020

Calculate peptide dosages

Learning how to calculate a peptide dose? Use our beginner-friendly peptide dosage, blend, and accumulation calculators. Enter vial size, reconstitution volume, and target dose to get exact draw volumes instantly. No guesswork, just clear guidance that helps prevent common mistakes.